TEXT 10.2770

PTO-1590 (8-01)

OS 274 SEQ. Access DB# SEARCH REQUEST FORM

S	cientific and Technic	al Information Center
Requester's Full Name: Bax Art Unit: 1041 Phone	o Thuy Nguy Number 30_8 - 424	(r) Examiner #: 73403 Date: 8/25/03
Mail Box and Bldg/Room Location		43 Serial Number: 09845, 726 sults Format Preferred (circle): PAPER DISK E-MAIL
If more than one search is subr	nitted, please priorit	ize searches in order of need.
Please provide a detailed statement of the Include the elected species or structures,	e search topic, and describ keywords, synonyms, acro s that may have a special n	e as specifically as possible the subject matter to be searched. onyms, and registry numbers, and combine with the concept or neaning. Give examples or relevant citations, authors, etc, if
Title of Invention: Biopo	slymarker.	<u> </u>
Inventors (please provide full names):		iki et al
Earliest Priority Filing Date:	4/30/01 :	
For Sequence Searches Only Please incli appropriate serial number.	ude all pertinent information	(parent child, divisional, or issued patent numbers) along with the
please searc		NO.1 specifically
'residues'	2-12.	
	·	
. please al	so searce	h pending database
& inventor.		
		"Medical and the second of the
	,	Mank You.
LB.		
1-11 mas	·· -	
STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: Hanly	NA Sequence (#)	STN
·		
Searcher Phone #:	AA Sequence (#)	Dialog
Searcher Phone #: Searcher Location:	AA Sequence (#)	DialogQuestel/Orbit
Searcher Location: Date Searcher Picked Up: 8/2 6		
Searcher Location: Date Searcher Picked Up: 5/2 Date Completed: 5/3	Structure (#) Bibliographic Litigation	Questel/Orbit Dr.Link Lexis/Nexis
Searcher Location: Date Searcher Picked Up: 8/2 6	Structure (#) Bibliographic	Questel/Orbit

BEST AVAILABLE COPY



STIC Search Report Biotech-Chem Library

STIC Database Tracking Number: 102274

TO: Bao-thuy Nguyen Location: CM1/7E05

Art Unit: 1641

Friday, August 29, 2003

Case Serial Number: 09845726

From: Susan Hanley

Location: Biotech-Chem Library

CM1 6B05

Phone: 305-4053

susan.hanley@uspto.gov

Search Notes	
	•
·	



```
=> d his
```

```
(FILE 'HOME' ENTERED AT 17:40:20 ON 29 AUG 2003)
     FILE 'CAPLUS' ENTERED AT 17:40:28 ON 29 AUG 2003
L1
             153 S JACKOWSKI G?/AU
L2
              35 S STANTON E?/AU
L3
              48 S THATCHER B?/AU
L4
              31 S YANTHA J?/AU
            3032 S MARSHALL J?/AU
L5
            3170 S L1-5
L6
              58 S L6 AND BIOPOLYMER
L7
L8
              89 S L6 AND MOLECULAR WEIGHT
              29 S L7 AND L8 - 29 cites
L9
                 SELECT RN L9 1-29
     FILE 'REGISTRY' ENTERED AT 17:42:57 ON 29 AUG 2003
L10
              29 S E1-29
                            29 cpds for L9 cites
     FILE 'CAPLUS' ENTERED AT 17:43:25 ON 29 AUG 2003
                                  29 cites & 29 apds displayed
L11
              29 S L10 AND L9
=> d ibib abs hitstr 1-29
L11 ANSWER 1 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:
                           2002:849935 CAPLUS
DOCUMENT NUMBER:
                           137:348846
TITLE:
                           Biopolymer marker indicative of disease
                           state having a molecular weight of
                           1845 daltons
                           Jackowski, George; Thatcher, Brad;
Marshall, John; Yantha, Jason;
INVENTOR(S):
                           Vrees, Tammy
                           Syn.X Pharma, Inc., Can.
PATENT ASSIGNEE(S):
SOURCE:
                           PCT Int. Appl., 27 pp.
                           CODEN: PIXXD2
DOCUMENT TYPE:
                           Patent
LANGUAGE:
                           English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                       KIND
                             DATE
                                              APPLICATION NO.
     WO 2002088747
                        A2
                              20021107
                                              WO 2002-CA633
                                                                 20020429
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
              PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
         UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
              BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2003013845
                        A1 20030116
                                              US 2001-846351
                                                                 20010430
PRIORITY APPLN. INFO.:
                                           US 2001-846351 A 20010430
     The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     the absence of said at least one disease state relative to recognition of
     the presence and/or the absence of said biopolymer.
IT
     473553-05-8
```

RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL

(Biological study); USES (Uses)

(biopolymer marker indicative of disease state having a mol. wt. of $1845 \, \text{daltons}$)

RN 473553-05-8 CAPLUS

L-Arginine, L-arginyl-L-asparaginylglycyl-L-phenylalanyl-L-lysyl-L-seryl-L-histidyl-L-alanyl-L-leucyl-L-glutaminyl-L-leucyl-L-asparaginyl-L-asparaginyl-L-asparaginyl-L-glutaminyl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 2-A

PAGE 3-A

PAGE 4-A

L11 ANSWER 2 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:849925 CAPLUS

DOCUMENT NUMBER:

137:348845

TITLE:

Biopolymer marker indicative of disease

state having a molecular weight of

1211 daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

Syn.X Pharma, Inc., Can. PCT Int. Appl., 30 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

1

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PAT	ENT i	NO.		KI	ND I	DATE			Al	PPLI	CATIO	ON NO). I	DATE			
					:								:				
WO	20020	U887:	31	A.	ζ.	2002.	1107		W	J 201	J2-U	4632		20020	J429		
	W:	ΑE,	AG,	AL,	ΑM,	AT,	ΑU,	ΑZ,	ΒA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DΕ,	DK,	DM,	DΖ,	ΕE,	ES,	FΙ,	GB,	GD,	GE,	GH,	GM,
		HR,	ΗU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,	LS,
		LT,	LU,	L۷,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NO,	ΝZ,	PL,	PT,	RO,
		RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TR,	Π,	ΤZ,	UA,	UG,	UΖ,	VN,
		ΥU,	ZA,	ΖW,	ΑM,	ΑZ,	ΒY,	KG,	ΚZ,	MD,	RU,	TJ,	TM				
	RW:	GH,	GM.	KE.	LS,	MW,	MZ.	SD,	SL,	SZ,	TZ.	UG.	ZM.	ZW.	AT,	BE.	CH.

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 2003004307 A1 20030102 US 2001-845731 20010430

PRIORITY APPLN. INFO.:

US 2001-845731 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-light detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

IT 473553-28-5

RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(biopolymer marker indicative of disease state having a mol. wt. of 1211 daltons) $\,$

RN 473553-28-5 CAPLUS

CN L-Leucine, L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

```
ACCESSION NUMBER:
                            2002:849924 CAPLUS
DOCUMENT NUMBER:
                            137:348844
TITLE:
                            Biopolymer marker indicative of disease
                            state having a molecular weight of
                            1690 daltons
INVENTOR(S):
                            Jackowski, George: Thatcher, Brad:
                            Vrees, Tammy; Yantha, Jason; Marshall,
                            John
                            Syn.X Pharma, Inc., Can.
PATENT ASSIGNEE(S):
                            PCT Int. Appl., 30 pp.
SOURCE:
                            CODEN: PIXXD2
DOCUMENT TYPE:
                            Patent
                            English
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                        KIND DATE
                                                APPLICATION NO. DATE
     WO 2002088727
                               20021107
                                                WO 2002-CA617
                         A2
                                                                   20020429
     WO 2002088727
                         Α3
                               20030103
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
              PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
         UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
              BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2002169278
                         A1
                               20021114
                                                US 2001-845730
                                                                   20010430
     US 6593298
                         B2
                               20030715
PRIORITY APPLN. INFO.:
                                             US 2001-845730 A 20010430
     The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer.
TT
     473552-58-8
```

RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(biopolymer marker indicative of disease state having a

mol. wt. of 1690 daltons)

473552-58-8 CAPLUS RN

CN L-Leucine, L-lysyl-L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-histidy1-L-tryptophy1-L-.alpha.-glutamy1-L-sery1-L-alany1-L-sery1-Lleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

Come

L11 ANSWER 4 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: DOCUMENT NUMBER:

2002:849923 CAPLUS

137:348791

TITLE:

Biopolymer marker indicative of disease

state having a molecular weight of

1406 daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad;

Vrees, Tammy; Yantha, Jason; Marshall,

PATENT ASSIGNEE(S):

SOURCE:

Syn.X Pharma, Inc., Can. PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088723	A2	20021107	WO 2002-CA611	20020426
WO 2002088723	A3	20030103		
W: AE, AG	AL, AM	I, AT, AU, AZ,	BA, BB, BG, BR, BY	, BZ, CA, CH, CN,
CO, CR	CU, CZ	, DE, DK, DM,	DZ, EC, EE, ES, F	[, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 2003040602 A1 20030227 US 2001-846347 20010430

PRIORITY APPLN. INFO.:

US 2001-846347 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

IT 263562-85-2

RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(biopolymer marker indicative of disease state having a mol. wt. of 1406 daltons)

RN 263562-85-2 CAPLUS

CN L-Lysine, L-.alpha.-aspartyl-L-alanyl-L-histidyl-L-lysyl-L-seryl-L-.alpha.glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

L11 ANSWER 5 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN ACCESSION NUMBER: 2002:849922 CAPLUS

```
DOCUMENT NUMBER:
                            137:348843
TITLE:
                            Biopolymer marker indicative of disease
                            state having a molecular weight of
                                                                     Same
                            2056 daltons
                            Jackowski, George; Thatcher, Brad;)
Marshall, John; Yantha, Jason;
INVENTOR(S):
                            Vrees, Tammy
                            Syn.X Pharma, Inc., Can.
PATENT ASSIGNEE(S):
SOURCE:
                            PCT Int. Appl., 27 pp.
                            CODEN: PIXXD2
DOCUMENT TYPE:
                            Patent
                            English
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                         KIND DATE
                                                 APPLICATION NO.
                                                 WO 2002-CA578
                                20021107
                                                                    20020425
     WO 2002088717
                          A2
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
          PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
               CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
               BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                             US 2001-845736
PRIORITY APPLN. INFO.:
                                                               A 20010430
     The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer.
     112805-24-0, Complement C3f (human)
     RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL
```

(Biological study); USES (Uses)

(biopolymer marker indicative of disease state having a

mol. wt. of 2056 daltons)

112805-24-0 CAPLUS RN

Complement C3f (human) (9CI) (CA INDEX NAME) CN

Absolute stereochemistry.

PAGE 1-A

HO'

PAGE 1-B

PAGE 2-B

L11 ANSWER 6 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN ACCESSION NUMBER: 2002:849921 CAPLUS

DOCUMENT NUMBER:

137:348842

TITLE:

Polymer marker indicative of disease state having a

INVENTOR(S):

Spile molecular weight of 1518 daltons. Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

PATENT ASSIGNEE(S):

Vrees, Tammy Syn.X Pharma, Inc., Can. PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

SOURCE:

Patent English

LANGUAGE: FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE WO 2002088716 20021107 WO 2002-CA577 Α2 20020425 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG PRIORITY APPLN. INFO.: US 2001-845765 A 20010430 The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. 25422-31-5, Fibrinopeptide A (human) RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (polymer marker indicative of disease state having a mol. wt. of 1518 daltons) RN 25422-31-5 CAPLUS

Absolute stereochemistry.

PAGE 1-A

Fibrinopeptide A (human) (7CI, 8CI, 9CI) (CA INDEX NAME)

PAGE 1-B

PAGE 2-B

CO₂H

L11 ANSWER 7 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833556 CAPLUS

DOCUMENT NUMBER:

137:334916

TITLE:

Alpha fibrinogen biopolymer marker

indicative of myocardial infarction having a

INVENTOR(S):

molecular weight of 1020 daltons Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy PATENT ASSIGNEE(S):

SOURCE:

Can.

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent English

LANGUAGE: FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO. DATE

```
US 2002161188
                        A1
                              20021031
                                              US 2001-846350
                                                                20010430
     US 659987.7
                        B2
                              20030729
     WO 2002088728
                        A2
                              20021107
                                              WO 2002-CA619
                                                                20020429
     WO 2002088728
                        Α3
                              20021227
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             CM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                           US 2001-846350 A 20010430
PRIORITY APPLN. INFO.:
     The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer. Serum samples
     were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the
     disease specific marker identified by the sequence DFLAEGGGVR and
     characterized as a .alpha. fibrinogen having a mol. wt
      . of 1020 daltons was found. This marker is indicative of myocardial
     infarction.
     59001-25-1, 7-16-Fibrinopeptide A (human)
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);
     USES (Uses)
        (alpha fibrinogen biopolymer marker of 1020 daltons
        indicative of myocardial infarction)
RN
     59001-25-1 CAPLUS
     7-16-Fibrinopeptide A (human) (9CI) (CA INDEX NAME)
```

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

L11 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: DOCUMENT NUMBER:

2002:833555 CAPLUS

137:334915

TITLE:

Apolipoprotein CIII biopolymer marker indicative of Type II diabetes having a molecular weight of 1097 daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

SOURCE:

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

Can.

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO.	KIND DATE	APPLICATION NO.	DATE
	WO 2002088743	A1 20021031 A2 20021107 A3 20030103	US 2001-846352 WO 2002-CA618	20010430 20020429
	W: AE, AG, CO, CR, GM, HR, LS, LT, PL, PT,	AL, AM, AT, AU, AZ, E CU, CZ, DE, DK, DM, D HU, ID, IL, IN, IS, I LU, LV, MA, MD, MG, M RO, RU, SD, SE, SG, S	DZ, EC, EE, ES, FI JP, KE, KG, KP, KR MK, MN, MW, MX, MZ SI, SK, SL, TJ, TM	, GB, GD, GE, GH, , KZ, LC, LK, LR, , NO, NZ, OM, PH, , TN, TR, TT, TZ,
	RW: GH, GM,	UZ, VN, YU, ZA, ZM, Z KE, LS, MW, MZ, SD, S DK, ES, FI, FR, GB, G	SL, SZ, TZ, UG, ZM	, ZW, AT, BE, CH,
DDTA	BF, BJ, RITY APPLN. INFO.	CF, CG, CI, CM, GA, C	GN, GQ, GW, ML, MR S 2001-846352 A	, NE, SN, TD, TG
AB		ention involves the us		
	steps in conjunc	ction with mass spect	roscopy and time-of	f-flight detection
	procedures to ma	eximize the diversity	of biopolymers wh	ich are
		in a particular sample		
		such a sample is ther st one particular disc		
		gain the ability to		
	absence of said	at least one disease	state relative to	recognition of the
		the absence of said l		
		/ SELDI-TOF using the		
		marker identified by a apolipoprotein CII		
	. of 1097 daltor	ns was found. This ma	arker is indicative	of Type II
	diabetes.			,,
IΤ	473550-31-1		d	neu (n'
		e); BSU (Biological si erties); ANST (Analyti		

Searched by Susan Hanley 305-4053

(apolipoprotein CIII biopolymer marker of 1097 daltons indicative of Type II diabetes)

473550-31-1 CAPLUS RN

L-Alanine, L-prolyl-L-.alpha.-glutamyl-L-valyl-L-arginyl-L-prolyl-L-CN threonyl-L-seryl-L-alanyl-L-valyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A HN ÒН (CH₂)₃

PAGE 1-B

L11 ANSWER 9 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833554 CAPLUS

DOCUMENT NUMBER:

137:334914

TITLE:

Complement C3f biopolymer marker indicative

of myocardial infarction and congestive heart failure

having a molecular weight of 1449

daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

SOURCE:

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161186	A1	20021031	US 2001-846349	20010430
US 6602855	B2	20030805		
WO 2002088726	A2	20021107	WO 2002-CA615	20020426
WO 2002088726	Α3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, CM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, PRIORITY APPLN. INFO.: A 20010430 US 2001-846349 The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence THRIHWESASLL and characterized as a complement C3f fragment having a mol. wt. of 1449 daltons was found. This marker is indicative of myocardial infarction, intracerebral hemorrhage, or congestive heart failure. 112821-21-3, Complement C3f RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic

use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (complement C3f biopolymer marker of 1449 daltons indicative of myocardial infarction and congestive heart failure)

RN 112821-21-3 CAPLUS

Complement C3f (9CI) (CA INDEX NAME) CN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

473549-42-7 TT

> RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);

(complement C3f biopolymer marker of 1449 daltons indicative of myocardial infarction and congestive heart failure)

RN 473549-42-7 CAPLUS

L-Leucine, L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-histidyl-Ltryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

```
L11 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
```

ACCESSION NUMBER:

2002:833553 CAPLUS

DOCUMENT NUMBER:

137:334913

TITLE:

Alpha fibrinogen biopolymer marker

INVENTOR(S):

indicative of renal failure having a molecular weight of 1206 daltons
Jackowski, George; Thatcher, Brad;
Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

Can.

SOURCE:

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND DATE	Ξ Α	PPLICATION NO.	DATE	
US 2002161185			S 2001-845725		
WO 2002088721			O 2002-CA609	20020426	
WO 2002088721					
				, BZ, CA, CH, CN,	
				G, GB, GD, GE, GH,	
				, KZ, LC, LK, LR,	
				, NO, NZ, OM, PH,	
				I, TN, TR, TT, TZ,	
				KZ, MD, RU, TJ, T	Μ
				I, ZW, AT, BE, CH,	
				C, NL, PT, SE, TR,	
			GQ, GW, ML, MF 001-845725 A	R, NE, SN, TD, TG	
PRIORITY APPLN. INFO AB The instant inv				on of preparatory	
				of-flight detection	
procedures to m					
verifiable with					
				to their ability t	۰.
evidence at lea					_
				er the presence or	
				recognition of the	
presence and/or					
				ICHIP system and the	
disease specifi					
characterized a					
	•	•	-		

. of 1206 daltons was found. This marker is indicative of renal failure.

59001-24-0, 5-16-Fibrinopeptide A (human)

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(alpha fibrinogen biopolymer marker of 1206 daltons

indicative of renal failure)

RN 59001-24-0 CAPLUS

CN 5-16-Fibrinopeptide A (human) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

L11 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833552 CAPLUS

DOCUMENT NUMBER:

TITLE:

Complement C3f biopolymer marker indicative

of myocardial infarction and congestive heart failure having a molecular weight of 1348

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

SOURCE:

Can.

U.S. Pat. Appl. Publ., 11 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.		DATE	APPLICATION NO.	DATE
US 2002161184	A1	20021031	US 2001-845715	20010430
WO 2002088720	A2	20021107	WO 2002-CA608	20020426

WO 2002088720 **A3** 20030206 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG PRIORITY APPLN. INFO.: US 2001-845715 A 20010430 The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence HRIHWESASLL and characterized as a complement C3f fragment having a mol. wt. of 1348 daltons was found. This marker is indicative of myocardial infarction, intracerebral hemorrhage, or congestive heart failure. IT 112821-21-3, Complement C3f RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (complement C3f biopolymer marker of 1348 daltons indicative of myocardial infarction and congestive heart failure) RN 112821-21-3 CAPLUS Complement C3f (9CI) (CA INDEX NAME) CN *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

473546-75-7 IT

> RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);

(complement C3f biopolymer marker of 1348 daltons indicative of myocardial infarction and congestive heart failure)

RN 473546-75-7 CAPLUS

L-Leucine, L-histidyl-L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A Мe CO₂H ŃΗ Et Bu-i

PAGE 1-B

```
O S NH NH NH2
```

```
L11 ANSWER 12 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
```

ACCESSION NUMBER: 2002:833551 CAPLUS

DOCUMENT NUMBER:

137:334911

TITLE:

Apolipoprotein E biopolymer marker

indicative of insulin resistance having a

molecular weight of 2267 daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad;) 9

Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

SOURCE:

Can. U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent English

LANGUAGE: FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161183	A1	20021031	US 2001-846348	20010430
WO 2002088745	A2	20021107	WO 2002-CA624	20020429
WO 2002088745	A3	20021227		
W: AE, AG,	AL, AM,	AT, AU, AZ,	BA, BB, BG, BR, BY	', BZ, CA, CH, CN,
			DZ, EC, EE, ES, FI	
GM, HR,	HU, ID,	IL, IN, IS,	JP, KE, KG, KP, KF	K. KZ. LC. LK. LR.
			MK, MN, MW, MX, MZ	
			SI, SK, SL, TJ, TN	
				G, KZ, MD, RU, TJ, TM
			SL, SZ, TZ, UG, ZN	
			GR, IE, IT, LU, MC	
			GN, GQ, GW, ML, MF	
PRIORITY APPLN. INFO			JS 2001-846348 A	
AD The feet of				

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence TVGSLAGQPLQERAQAWGERL and characterized as a apolipoprotein E having a mol. wt

. of 2267 daltons was found. This marker is indicative of insulin resistance.

IT 473546-72-4

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(apolipoprotein E biopolymer marker indicative of insulin resistance having a mol. wt. of 2267 daltons)

RN 473546-72-4 CAPLUS

CN L-Leucine, L-threonyl-L-valylglycyl-L-seryl-L-leucyl-L-alanylglycyl-L-glutaminyl-L-prolyl-L-leucyl-L-glutaminyl-L-.alpha.-glutamyl-L-arginyl-L-alanyl-L-glutaminyl-L-alanyl-L-tryptophylglycyl-L-.alpha.-glutamyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. .

PAGE 1-B

PAGE 2-A

ļ

PAGE 2-B

O
O
H
N
H
S
Me
H
N
S
Bu-i

PAGE 2-C

OH O S Pr-i NH2 NH2 O OH

IT 9004-10-8, Insulin, biological studies

RL: ADV (Adverse effect, including toxicity); BSU (Biological study,

unclassified); BIOL (Biological study)

(resistance; apolipoprotein E biopolymer marker indicative of

insulin resistance having a mol. wt. of 2267

daltons)

RN 9004-10-8 CAPLUS CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L11 ANSWER 13 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833550 CAPLUS

DOCUMENT NUMBER: TITLE:

137:334910

Complement C3f biopolymer marker indicative

of myocardial infarction and congestive heart failure

having a molecular weight of 1865

daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad;

Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

Can.

SOURCE: U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

[. 1

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO. DATE

```
20021031
                                             US 2001-846345
                                                               20010430
     US 2002161182
                       Α1
                             20021107
                                             WO 2002-CA622
                                                               20020429
     WO 2002088174
                        Α2
     WO 2002088174
                        A3
                             20030116
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                          US 2001-846345
                                                           A 20010430
     The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer. Serum samples
     were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the
     disease specific marker identified by the sequence SSKITHRIHWESASLL and
     characterized as a complement C3f fragment having a mol.
     wt. of 1865 daltons was found. This marker is indicative of
     myocardial infarction, intracerebral hemorrhage, Type II diabetes, or
     congestive heart failure.
     112821-21-3, Complement C3f
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
        (complement C3f biopolymer marker of 1865 daltons indicative
        of myocardial infarction and congestive heart failure)
RN
     112821-21-3 CAPLUS
     Complement C3f (9CI) (CA INDEX NAME)
CN
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT
     473546-71-3
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);
     USES (Uses)
        (complement C3f biopolymer marker of 1865 daltons indicative
        of myocardial infarction and congestive heart failure)
     473546-71-3 CAPLUS
RN
     L-Leucine, L-seryl-L-seryl-L-lysyl-L-isoleucyl-L-threonyl-L-histidyl-L-
     arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-
     alanyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)
```

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

L11 ANSWER 14 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833549 CAPLUS

DOCUMENT NUMBER: TITLE:

137:334909

Complement C3f biopolymer marker indicative of myocardial infarction and congestive heart failure

having a molecular weight of 2021

daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

Can.

SOURCE:

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO. DATE

```
US 2002161181
                             20021031
                                             US 2001-846344
                       A1
                                                               20010430
                                             WO 2002-CA627
     WO 2002088711
                             20021107
                        A2
                                                               20020429
     WO 2002088711
                        Α3
                             20030116
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                          US 2001-846344
                                                           A 20010430
     The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer. Serum samples
     were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the
     disease specific marker identified by the sequence SSKITHRIHWESASLLR and
     characterized as a complement C3f fragment having a mol.
     wt. of 2021 daltons was found. This marker is indicative of
     myocardial infarction, Type II diabetes, or congestive heart failure.
     112821-21-3, Complement C3f
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
        (complement C3f biopolymer marker of 2021 daltons indicative
        of myocardial infarction and congestive heart failure)
     112821-21-3 CAPLUS
RN
CN
     Complement C3f (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
     112805-24-0, Complement C3f (human)
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);
     USES (Uses)
        (complement C3f biopolymer marker of 2021 daltons indicative
        of myocardial infarction and congestive heart failure)
     112805-24-0 CAPLUS
RN
     Complement C3f (human) (9CI) (CA INDEX NAME)
CN
Absolute stereochemistry.
```

PAGE 1-A

H0'

PAGE 1-B

PAGE 2-B

L11 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN ACCESSION NUMBER: 2002:833548 CAPLUS

DOCUMENT NUMBER: 137:334908

TITLE: Complement C4A biopolymer marker indicative

NGUYEN 09/845,726

```
of myocardial infarction and congestive heart failure
                           having a molecular weight of 1896
                           daltons
                           Jackowski, George; Thatcher, Brad;
INVENTOR(S):
                                                                   garl
                           Marshall, John; Yantha, Jason;
                           Vrees, Tammy
PATENT ASSIGNEE(S):
                           Can.
SOURCE:
                           U.S. Pat. Appl. Publ., 10 pp.
                           CODEN: USXXCO
DOCUMENT TYPE:
                           Patent
LANGUAGE:
                           English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                        KIND
                              DATE
                                               APPLICATION NO.
                                                                 DATE
                              20021031
     US 2002161180
                        Α1
                                               US 2001-846343
                                                                  20010430
                              20021107
     WO 2002088724
                         Α2
                                               WO 2002-CA612
                                                                  20020426
     WO 2002088724
                              20030103
                         Α3
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
              UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                           US 2001-846343 A 20010430
     The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer. Serum samples
     were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the
     disease specific marker identified by the sequence NGFKSHALQLNNRQIR and
     characterized as a complement C4A fragment having a mol.
     wt. of 1896 daltons was found. This marker is indicative of
     myocardial infarction, Type II diabetes, and congestive heart failure.
     80295-48-3, Complement C4
IT
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
        (C4A; complement C4A biopolymer marker of 1896 daltons
        indicative of myocardial infarction and congestive heart failure)
RN
     80295-48-3 CAPLUS
CN
     Complement C4 (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
     473546-69-9
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);
     USES (Uses)
        (complement C4A biopolymer marker of 1896 daltons indicative
        of myocardial infarction and congestive heart failure)
RN
     473546-69-9 CAPLUS
     L-Arginine, L-asparaginylglycyl-L-phenylalanyl-L-lysyl-L-seryl-L-histidyl-
     L-alanyl-L-leucyl-L-glutaminyl-L-leucyl-L-asparaginyl-L-asparaginyl-L-
```

arginyl-L-glutaminyl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

PAGE 2-A

PAGE 3-A

PAGE 4-A

L11 ANSWER 16 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: DOCUMENT NUMBER:

2002:833547 CAPLUS 137:334907

TITLE:

Alpha fibrinogen **biopolymer** marker

indicative of renal failure or intracerebral

hemorrhage having a molecular weight

of 1465 daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy

Can.

PATENT ASSIGNEE(S):

SOURCE:

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

•	
PATENT NO. KIND DATE APPLICATION NO. DATE	
US 2002161179 A1 20021031 US 2001-845719 20010430	
WO 2002088715 A2 20021107 WO 2002-CA576 20020425	
WO 2002088715 A3 20030116	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, G	
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, G	GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, I	
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, I	
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,	
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,	
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, G	
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,	TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, ⁻	TG
PRIORITY APPLN. INFO.: US 2001-845719 A 20010430	
AB The instant invention involves the use of a combination of preparator	ry
steps in conjunction with mass spectroscopy and time-of-flight detec	tion
procedures to maximize the diversity of biopolymers which are	
verifiable within a particular sample. The cohort of biopolymers	

verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence DSGEGDFLAEGGGVR and characterized as a .alpha. fibrinogen having a mol. wt
. of 1465 daltons was found. This marker is indicative of renal failure

or intracerebral hemorrhage.
IT 107012-96-4, 2-16-Fibrinopeptide A (human)

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(alpha fibrinogen biopolymer marker of 1465 daltons indicative of renal failure or intracerebral hemorrhage)

RN 107012-96-4 CAPLUS

CN 2-16-Fibrinopeptide A (human) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-C

```
S CO<sub>2</sub>H
```

```
L11 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:
                             2002:833546 CAPLUS
DOCUMENT NUMBER:
                             137:334906
TITLE:
                             Serum albumin biopolymer marker indicative
                             of insulin resistance having a molecular
                             weight of 2937 daltons
Jackowski, George; Thatcher, Brad;
Marshall, John; Yantha, Jason;
INVENTOR(S):
                             Vrees, Tammy
PATENT ASSIGNEE(S):
                             Can.
                             U.S. Pat. Appl. Publ., 10 pp. CODEN: USXXCO
SOURCE:
DOCUMENT TYPE:
                             Patent
LANGUAGE:
                             English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
```

	PATENT NO.	KIND	DATE		APPLICA	TION N	ο.	DATE			
	US 2002161177 WO 2002088742 WO 2002088742	A2	20021107		US 2001 WO 2002						
	W: AE, AG, CO, CR, GM, HR, LS, LT, PL, PT, UA, UG,	AL, AM CU, CZ HU, ID LU, LV RO, RU UZ, VN	, AT, AU, , DE, DK, , IL, IN, , MA, MD, , SD, SE, , YU, ZA,	DM, DZ IS, JF MG, Mk SG, SI ZM, ZW	(, EC, E), KE, K (, MN, M (, SK, S), AM, A	E, ES, G, KP, W, MX, L, TJ, Z, BY.	FI KR MZ TM	GB, KZ, NO, TN,	GD, LC, NZ, TR, MD.	GE, LK, OM, TT, RU.	GH, LR, PH, TZ, TJ. TM
	RW: GH, GM, CY, DE,	KE, LS DK, ES	, MW, MZ, , FI, FR,	SD, SL GB, GR	, SZ, T , IE, I	Z, UG, T, LU,	ZM, MC,	ZW,	AT, PT,	BE, SE.	CH, TR,
DDTO	BF, BJ, RITY APPLN. INFO	CF, CG	, CI, CM,	GA, GN	, GQ, G 2001-84	W, ML,	MR,	NE,	SN,	TD,	TG
AB	The instant inv		involves t							irato	orv
	steps in conjun	ction w	ith mass s	pectro	scopy a	nd time	e-of	-flig	ht c	lete	ction
	procedures to ma	aximize	the diver	sity o	f biopo	lymers	whi	ich ar	·e		
	verifiable with verified within										1344
•	evidence at leas	Sucii a st one i	sampie is narticular	. disea	se stat	WILD TO	er. rehv	TO TH	leir	abı	iity to
	diagnostician to	o gain	the abilit	v to c	haracte	rize e	ithe	r the	pre	sen	ce or
	absence of said	at lea:	st one dis	ease s	tate re	lative	to	recog	niti	on o	of the
	presence and/or	the ab	sence of s	aid bi	opolyme	r. Se	rum	sampl	es		
	were analyzed by disease specific						EINC	HIP s	yste	em ai	nd the
	DAHKSEVAHRFKDLG	FNEKAL	/ITA and c	eu by haract	erized	uence	orun	ı əlbu	min	hav:	ina a
	mol. wt. of 293	7 dalto	ns was fou	ind. T	his mar	ker is	CT UII	ı aıbu		IIav	iliy a
	indicative of i										
ΙT	9004-10-8, Insu					55			_		
	<pre>RL: ADV (Adverse unclassified); {</pre>					R20 (I	вто	og1 ca	ı st	udy	,
	(resistance;					er of :	2937	' dalt	ons		
	indicative of										
RN	9004-10-8 CAPLI										
CN	Insulin (9CI)	(CA IND	EX NAME)								

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 473546-58-6

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(serum albumin biopolymer marker of 2937 daltons indicative of insulin resistance)

RN 473546-58-6 CAPLUS

CN

L-Alanine, L-.alpha.-aspartyl-L-alanyl-L-histidyl-L-lysyl-L-seryl-L.alpha.-glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl-Llysyl-L-.alpha.-aspartyl-L-leucylglycyl-L-.alpha.-glutamyl-L-.alpha.glutamyl-L-asparaginyl-L-phenylalanyl-L-lysyl-L-alanyl-L-leucyl-L-valyl-Lleucyl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

PAGE 1-C

PAGE 1-D

PAGE 2-D

__Et

```
ACCESSION NUMBER:
                           2002:833503 CAPLUS
DOCUMENT NUMBER:
                           137:334905
TITLE:
                           Serum albumin biopolymer marker indicative
                           of renal failure having a molecular
                           weight of 1521 daltons
INVENTOR(S):
                           Jackowski, George; Thatcher, Brad;
                           Marshall, John; Yantha, Jason;
                           Vrees, Tammy
PATENT ASSIGNEE(S):
                           Can.
                           U.S. Pat. Appl. Publ., 10 pp.
SOURCE:
                           CODEN: USXXCO
DOCUMENT TYPE:
                           Patent
LANGUAGE:
                           English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                       KIND DATE
                                              APPLICATION NO.
                                                                 DATE
     US 2002160958
                        Α1
                              20021031
                                              US 2001-845764
                                                                 20010430
     WO 2002088713
                              20021107
                                              WO 2002-CA631
                        Α2
                                                                 20020429
     WO 2002088713
                        Α3
                              20021227
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
         UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
              BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                           US 2001-845764
PRIORITY APPLN. INFO.:
                                                            A 20010430
     The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer. Serum samples
     were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the
     disease specific marker identified by the sequence DAHKSEVAHRFKD and
     characterized as a serum albumin having a mol. wt. of
     1521 daltons was found. This marker is indicative of renal failure.
TT
     473552-37-3
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);
     USES (Uses)
        (serum albumin biopolymer marker of 1521 daltons indicative
        of renal failure)
RN
     473552-37-3 CAPLUS
     L-Aspartic acid, L-.alpha.-aspartyl-L-alanyl-L-histidyl-L-lysyl-L-seryl-L-
CN
     .alpha.-qlutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl-L-
     lysyl- (9CI) (CA INDEX NAME)
Absolute stereochemistry.
```

L11 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

PAGE 1-A

PAGE 1-B

ΙT 474276-98-7

RL: PRP (Properties)

(unclaimed sequence; serum albumin biopolymer marker indicative of renal failure having a mol. wt. of

1521 daltons)

RN 474276-98-7 CAPLUS

L-Leucine, L-arginyl-L-.alpha.-aspartyl-L-alanyl-L-histidyl-L-lysyl-L-CN seryl-L-.alpha.-glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-Lphenylalanyl-L-lysyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

```
(CH<sub>2</sub>)<sub>4</sub>
     i-Pr
                                                               (CH<sub>2</sub>)<sub>3</sub>
                                                                                             NH<sub>2</sub> HN
              ö
                                                                                   H02C
                            Мe
__CO2H
                                                                                                              0
                                                                                                                            CO2H
```

L11 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833430 CAPLUS

DOCUMENT NUMBER:

137:334904

TITLE:

Serum amyloid A biopolymer marker indicative of myocardial infarction having a molecular

weight of 1525 daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

SOURCE:

Can.

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

	PAT	ENT I	NO.		KIN		DATE			Al	PPLI	CATIO	ON NO	o.	DATE				
	WO WO	2002 2002	0887 0887	30 30	A: A: A:	L 2 3	2002: 2002: 2002: 2003:	1107 1227			5 200 0 200			_	2001(2002(0430 0429			
PRIOR	ITY The ste	RW: APPins	AE, CO, GM, LS, PL, UA, GH, CY, BF, LN. tant	AG, CR, HR, LT, PT, OM, DE, BJ, INFO invento ma	AL, CU, HU, RO, UZ, KE, DK, CF, ::	AM, CZ, ID, LV, RU, VN, LS, CG, on i	AT, DE, IL, MA, SD, YU, MW, FI, CI, nvoluth ma	AU, DK, IN, MD, SE, ZA, MZ, FR, CM,	DM, IS, MG, SG, SD, GB, GA, the I	DZ, JP, MK, SI, ZW, GR, GN, JS 20 troso	EC, KE, MN, SK, AM, SZ, IE, GQ, Of a copy bio	EE, KG, MW, SL, AZ, TZ, IT, GW, 34677 comb	ES, KP, MX, TJ, BY, UG, LU, ML, 79 oina time	FI, KR, MZ, TM, KG, ZM, MC, MR, a tion e-of whi	GB, KZ, NO, TN, KZ, NL, NE, 2001(of	GD, LC, NZ, TR, MD, AT, PT, SN, 0430 prepa	GE, LK, OM, TT, RU, BE, SE, TD,	GH, LR, PH, TZ, TJ, CH, TR, TG	
	ver evi	ifie denc	d wi [.] e at	thin lea:	such st or	n a ne p	ticu samp artic he al	le i: cula	s the r dis	en v [.] sease	iewed e sta	d wit ate;	th ro	ef. reby	to ti enal	heir bling	abi ⁻ ga	•	

absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence PNHFRPAGLPEKY and characterized as a serum amyloid A having a mol. wt. of 1525 daltons was found. This marker is indicative of myocardial infarction.

IT 331450-30-7

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(serum amyloid A biopolymer marker of 1525 daltons indicative of myocardial infarction)

RN 331450-30-7 CAPLUS

CN L-Tyrosine, L-prolyl-L-asparaginyl-L-histidyl-L-phenylalanyl-L-arginyl-L-prolyl-L-alanylglycyl-L-leucyl-L-prolyl-L-alpha.-glutamyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

L11 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:833429 CAPLUS

DOCUMENT NUMBER: 137:334903

TITLE: Complement C3f biopolymer marker indicative

of Type II diabetes having a molecular

weight of 1998 daltons

INVENTOR(S):
Jackowski, George; Thatcher, Brad;

```
Marshall, John; Yantha, Jason;
                           Vrees, Tammy
PATENT ASSIGNEE(S):
                           Can.
SOURCE:
                           U.S. Pat. Appl. Publ., 10 pp.
                           CODEN: USXXCO
DOCUMENT TYPE:
                           Patent
LANGUAGE:
                           English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                        KIND DATE
                                               APPLICATION NO. DATE
                                                  . . . . . . . . . . . . . . . .
     US 2002160532
                         Α1
                              20021031
                                               US 2001-846346
                                                                  20010430
     WO 2002088707
                              20021107
                                               WO 2002-CA616
                                                                  20020429
                         Α2
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
              UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
              CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                            US 2001-846346
                                                             A 20010430
PRIORITY APPLN. INFO.:
     The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer. Serum samples
     were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the
     disease specific marker identified by the sequence SSKITHRIHWESASLLR and
     characterized as a complement C3f fragment having a mol.
     wt. of 1998 daltons was found. This marker is indicative of Type
     II diabetes.
     112821-21-3, Complement C3f
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
         (complement C3f biopolymer marker of 1998 daltons indicative
        of type II diabetes)
RN
     112821-21-3 CAPLUS
     Complement C3f (9CI) (CA INDEX NAME)
CN
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
     112805-24-0, Complement C3f (human)
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);
```

(complement C3f biopolymer marker of 1998 daltons indicative

Absolute stereochemistry.

of type II diabetes) 112805-24-0 CAPLUS

Complement C3f (human) (9CI) (CA INDEX NAME)

USES (Uses)


RN

PAGE 1-A

H0^

PAGE 1-B

PAGE 2-B



L11 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN ACCESSION NUMBER: 2002:833428 CAPLUS

DOCUMENT NUMBER:

137:333522

TITLE:

Biopolymer marker indicative of disease

state having a molecular weight of

2753 daltons

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; INVENTOR(S):

Vrees, Tammy

PATENT ASSIGNEE(S):

Can.

SOURCE:

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent English

LANGUAGE:

1

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO KIND DATE	APPLICATION NO.	DATE
	US 2002160531 A1 20021031 WO 2002088710 A2 20021107 WO 2002088710 A3 20021227	WO 2002-CA626	
	W: AE, AG, AL, AM, AT, AU, CO, CR, CU, CZ, DE, DK, GM, HR, HU, ID, IL, IN, LS, LT, LU, LV, MA, MD, PL, PT, RO, RU, SD, SE,	AZ, BA, BB, BG, BR, BY DM, DZ, EC, EE, ES, FI IS, JP, KE, KG, KP, KR MG, MK, MN, MW, MX, MZ SG, SI, SK, SL, TJ, TM	, GB, GD, GE, GH, , KZ, LC, LK, LR, , NO, NZ, OM, PH, , TN, TR, TT, TZ,
	UA, UG, UZ, VN, YU, ZA, RW: GH, GM, KE, LS, MW, MZ, CY, DE, DK, ES, FI, FR, BF, BJ, CF, CG, CI, CM,	SD, SL, SZ, TZ, UG, ZM GB, GR, IE, IT, LU, MC	, ZW, AT, BE, CH, , NL, PT, SE, TR,
PRIC	RITY APPLN. INFO.:	US 2001-846328 A	
AB	The instant invention involves		
	steps in conjunction with mass procedures to maximize the dive verifiable within a particular verified within such a sample i evidence at least one particula diagnostician to gain the abili absence of said at least one di presence and/or the absence of	spectroscopy and time-orsity of biopolymers who sample. The cohort of los then viewed with ref. In disease state; thereby to characterize eithereby to sease state relative to	F-flight detection ich are piopolymers to their ability to renabling a er the presence or
IT	98420-25-8		
	<pre>RL: ANT (Analyte); DGN (Diagnos (Biological study); USES (Uses) (biopolymer marker indicativ mol. wt. of 2753 daltons)</pre>	-	-
RN	98420-25-8 CAPLUS		
CN	L-Leucine, Lalphaaspartyl-L .alphaglutamyl-L-valyl-L-alan lvsvl-Lalphaaspartyl-L-leuc	yl-L-histidyl-L-arginyl	-L-phenylalanyl-L-

glutamyl-L-asparaginyl-L-phenylalanyl-L-lysyl-L-alanyl-L-leucyl-L-valyl-

Absolute stereochemistry.

(9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 1-C

PAGE 2-C

- IT 9004-10-8, Insulin, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (resistance; biopolymer marker indicative of disease state
 having a mol. wt. of 2753 daltons)
- RN 9004-10-8 CAPLUS
- CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CN

```
L11 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:
                           2002:833426 CAPLUS
DOCUMENT NUMBER:
                           137:334902
TITLE:
                           Complement C3f biopolymer marker indicative
                           of myocardial infarction or congestive heart failure
                           having a molecular weight of 1562
                           daltons
INVENTOR(S):
                           Jackowski, George; Thatcher, Brad;
                           Vrees, Tammy; Yantha, Jason; Marshall,
                           John
PATENT ASSIGNEE(S):
                           Can.
SOURCE:
                           U.S. Pat. Appl. Publ., 10 pp.
                           CODEN: USXXCO
DOCUMENT TYPE:
                           Patent
LANGUAGE:
                           English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                       KIND DATE
                                              APPLICATION NO.
                                                                DATE
     US 2002160529
                        A1
                              20021031
                                              US 2001-845738
                                                                20010430
     WO 2002088729
                              20021107
                                              WO 2002-CA629
                        A2
                                                                20020429
     WO 2002088729
                        А3
                              20021227
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
              PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
         UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
              CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
              BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                           US 2001-845738
                                                            A 20010430
     The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer. Serum samples
     were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the
     disease specific marker identified by the sequence ITHRIHWESASLL and
     characterized as a complement C3f fragment having a mol.
     wt. of 1562 daltons was found. This marker is indicative of
     myocardial infarction or congestive heart failure.
     112821-21-3, Complement C3f
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
        (complement C3f biopolymer marker of 1562 daltons indicative
        of myocardial infarction or congestive heart failure)
RN
     112821-21-3 CAPLUS
CN
     Complement C3f (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT
     473552-36-2
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);
        (complement C3f biopolymer marker of 1562 daltons indicative
        of myocardial infarction or congestive heart failure)
     473552-36-2 CAPLUS
RN
```

L-Leucine, L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-

histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

L11 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833425 CAPLUS

DOCUMENT NUMBER: TITLE: 137:334901 Alpha fibrinogen biopolymer marker

indicative of myocardial infarction or renal failure

having a molecular weight of 1350

daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad;

Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

Can.

SOURCE:

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO. DATE

```
US 2002160528
                       A1
                            20021031
                                            US 2001-845729
                                                              20010430
     WO 2002088722
                            20021107
                       A2
                                            WO 2002-CA610
                                                              20020426
     WO 2002088722
                       Α3
                             20021227
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                         US 2001-845729
                                                          A 20010430
     The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer. Serum samples
     were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the
     disease specific marker identified by the sequence SESDFLAEGGGVR and
     characterized as a .alpha. fibrinogen having a mol. wt
     . of 1350 daltons was found. This marker is indicative of myocardial
     infarction or renal failure.
     473552-35-1
TT
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);
     USES (Uses)
        (alpha fibrinogen biopolymer marker of 1350 daltons
        indicative of myocardial infarction or renal failure)
RN
     473552-35-1 CAPLUS
     L-Arginine, L-seryl-L-.alpha.-glutamyl-L-seryl-L-.alpha.-aspartyl-L-
     phenylalanyl-L-leucyl-L-alanyl-L-.alpha.-glutamylglycylglycylglycyl-L-
     valyl- (9CI) (CA INDEX NAME)
```

```
NH2
   HŇ.
CO2H
                            CO<sub>2</sub>H
```

L11 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833402 CAPLUS

DOCUMENT NUMBER:

137:334900

TITLE:

Complement C3f biopolymer marker indicative

of myocardial infarction and congestive heart failure having a molecular weight of 1777

APPLICATION NO. DATE

daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

SOURCE:

Can. U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent English

KIND DATE

LANGUAGE: FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.

	US 2002160434 A1	20021031	US 2001-845735	20010430				
	WO 2002088712 A2	20021107	WO 2002-CA628	20020429				
	W: AE, AG, AL, A	M, AT, AU, AZ,	BA, BB, BG, BR, BY	, BZ, CA, CH, CN,				
	CO, CR, CU, C	Z, DE, DK, DM,	DZ, EC, EE, ES, FI	, GB, GD, GE, GH,				
	GM, HR, HU, I	D, IL, IN, IS,	JP, KE, KG, KP, KR	, KZ, LC, LK, LR,				
			MK, MN, MW, MX, MZ					
			SI, SK, SL, TJ, TM					
				, KZ, MD, RU, TJ, TM				
			SL, SZ, TZ, UG, ZM					
	CY, DE, DK, E	S, FI, FR, GB,	GR, IE, IT, LU, MC	, NL, PT, SE, TR,				
	BF, BJ, CF, C	G, CI, CM, GA,	GN, GQ, GW, ML, MR	, NE, SN, TD, TG				
PRI	ORITY APPLN. INFO.:		US 2001-845735 A	20010430				
AB	The instant inventior							
	steps in conjunction with mass spectroscopy and time-of-flight detection							
	procedures to maximize the diversity of biopolymers which are							
	verifiable within a particular sample. The cohort of biopolymers							
	verified within such a sample is then viewed with ref. to their ability to							
	evidence at least one particular disease state; thereby enabling a							
	diagnostician to gair	the ability t	o characterize eith	er the presence or				
	absence of said at le							
	presence and/or the a							
	were analyzed by SELD	I-TOF using th	e Ciphergen PROTEIN	CHIP system and the				
	disease specific mark	er identified	by the sequence SKI	THRIHWESASLL and				
	characterized as a co	mplement C3f f	ragment having a mo	1.				
	wt. of 1777 daltons was found. This marker is indicative of							
	myocardial infarctior	, intracerebra	l hemorrhage, Type	II diabetes, or				
	congestive heart fail		2 / 2.	·				
ΙT	112821-21-3, Compleme	nt C3f						
	RL: ANT (Analyte); BS							

use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (complement C3f biopolymer marker of 1777 daltons indicative of myocardial infarction and congestive heart failure) RN 112821-21-3 CAPLUS Complement C3f (9CI) (CA INDEX NAME) CN *** STRUCTURE DIAGRAM IS NOT AVAILABLE *** 473546-15-5 IT RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); (complement C3f biopolymer marker of 1777 daltons indicative of myocardial infarction and congestive heart failure) RN 473546-15-5 CAPLUS L-Leucine, L-seryl-L-lysyl-L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-L-CN isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-Lseryl-L-leucyl- (9CI) (CA INDEX NAME)

PAGE 1-A

L11 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833398 CAPLUS

DOCUMENT NUMBER:

137:334899

TITLE:

Alpha fibrinogen biopolymer marker

indicative of myocardial infarction having a

molecular weight of 1536 daltons Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; INVENTOR(S):

Vrees, Tammy

PATENT ASSIGNEE(S):

Can.

SOURCE:

U.S. Pat. Appl. Publ., 10 pp. CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
	A1 20021031	US 2001-846780	20010430
	A2 20021107	WO 2002-CA579	20020425
WO 2002088718	A3 20021227		
	AL, AM, AT, AU, AZ,	BA, BB, BG, BR, BY	. BZ. CA. CH. CN.
	CU, CZ, DE, DK, DM,		
	HU, ID, IL, IN, IS,		
	LU, LV, MA, MD, MG,		
	RO, RU, SD, SE, SG,		
			, KZ, MD, RU, TJ, TM
The state of the s			
	KE, LS, MW, MZ, SD,		
	DK, ES, FI, FR, GB,		
	CF, CG, CI, CM, GA,		
PRIORITY APPLN. INFO		US 2001-846780 A	
	ention involves the		
steps in conjun	ction with mass spec	troscopy and time-o	f-flight detection
procedures to m	aximize the diversit	y of biopolymers wh	ich are
verifiable with	in a particular samp	le. The cohort of I	piopolymers
			to their ability to
	st one particular di		
	o gain the ability t		
	at least one diseas		
	the absence of said		
	y SELDI-TOF using th	• •	
were analyzed b	y secot-tor using th	e Cipileigen Pkolein	enir system and the

disease specific marker identified by the sequence ADSGEGDFLAEGGGVR and characterized as a .alpha. fibrinogen having a mol. wt . of 1536 daltons was found. This marker is indicative of myocardial infarction.

IT 25422-31-5, Fibrinopeptide A (human)

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic usé); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(alpha fibrinogen biopolymer marker of 1536 daltons indicative of myocardial infarction)

RN 25422-31-5 CAPLUS

CN Fibrinopeptide A (human) (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

PAGE 2-B

CO₂H

L11 ANSWER 26 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: DOCUMENT NUMBER:

2002:833397 CAPLUS

137:334898

TITLE:

Alpha fibrinogen biopolymer marker

indicative of myocardial infarction having a

APPLICATION NO. DATE

molecular weight of 1077 daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

SOURCE:

Can.

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

LANGUAGE:

Patent English

KIND DATE

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.

US 2002160422 A1 20021031 US 2001-846342 20010430								
WO 2002088708 A2 20021107 WO 2002-CA620 20020429								
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,	CN,							
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE,	GH.							
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,	LR.							
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM,	PH.							
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,	TZ.							
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,	MT , CT							
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,	CH,							
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,								
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,	TG							
PRIORITY APPLN. INFO.: US 2001-846342 A 20010430								
AB The instant invention involves the use of a combination of preparate	ory							
steps in conjunction with mass spectroscopy and time-of-flight deter	ction							
procedures to maximize the diversity of biopolymers which are								
verifiable within a particular sample. The cohort of biopolymers								
verified within such a sample is then viewed with ref. to their abi	lity to							
evidence at least one particular disease state; thereby enabling a	•							
diagnostician to gain the ability to characterize either the present	ce or							
absence of said at least one disease state relative to recognition o	of the							
presence and/or the absence of said biopolymer. Serum samples								
were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system a	nd the							
disease specific marker identified by the sequence GDFLAEGGGVR and								
characterized as a .alpha. fibrinogen having a mol. wt								
. of 1077 daltons was found. This marker is indicative of myocardia	al							
infarction.								
IT 473551-61-0								
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagno	ostic							
RE. ANT (Analyte), 630 (Blological Study, unclassified), but (Blagin	JSLIC							

use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(alpha fibrinogen biopolymer marker of 1077 daltons

indicative of myocardial infarction)

RN 473551-61-0 CAPLUS

CN L-Arginine, glycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-leucyl-L-alanyl-L-.alpha.-glutamylglycylglycylglycyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

L11 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833394 CAPLUS

DOCUMENT NUMBER:

137:334897

TITLE:

Complement C3f biopolymer marker indicative

of congestive heart failure having a molecular

weight of 1793 daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy Can.

PATENT ASSIGNEE(S):

SOURCE:

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ÚS 2002160419	A1	20021031	US 2001-845739	20010430
WO 2002088725	A2	20021107	WO 2002-CA614	20020426
WO 2002088725	Α3	20030103		
W: AE, AG,	AL, AM	, AT, AU, AZ,	BA, BB, BG, BR, BY	, BZ, CA, CH, CN,
CO, CR,	CU, CZ	, DE, DK, DM,	DZ, EC, EE, ES, FI	, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG PRIORITY APPLN. INFO.: US 2001-845739 A 20010430 The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence SKITHRIHWESASLL and characterized as a complement C3f fragment having a mol. wt. of 1793 daltons was found. This marker is indicative of congestive heart failure. 112821-21-3, Complement C3f RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (complement C3f biopolymer marker of 1793 daltons indicative of congestive heart failure) RN 112821-21-3 CAPLUS Complement C3f (9CI) (CA INDEX NAME) CN *** STRUCTURE DIAGRAM IS NOT AVAILABLE *** IT 473546-15-5 RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); (complement C3f biopolymer marker of 1793 daltons indicative

of congestive heart failure)

RN 473546-15-5 CAPLUS

L-Leucine, L-seryl-L-lysyl-L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-Lisoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-Lseryl-L-leucyl- (9CI) (CA INDEX NAME)

PAGE 1-A

```
L11 ANSWER 28 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
```

ACCESSION NUMBER:

2002:833393 CAPLUS

DOCUMENT NUMBER:

137:334896

TITLE:

Biopolymer marker indicative of Syndrome X

disease state having a molecular

weight of 1949 daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

SOURCE:

Can.

U.S. Pat. Appl. Publ., 9 pp.

CODEN: USXXCO Patent

DOCUMENT TYPE:

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT NO.	KIND DATE	APPLICATION NO.	DATE			
US 2002160418 WO 2002088746	A2 2002110	US 2001-845727 WO 2002-CA625	20010430 20020429			
CO, CR, GM, HR,	AL, AM, AT, AL CU, CZ, DE, DK HU, ID, IL, IN	./ J, AZ, BA, BB, BG, BR, BY, K, DM, DZ, EC, EE, ES, FI, J, IS, JP, KE, KG, KP, KR, D, MG, MK, MN, MW, MX, MZ,	GB, GD, GE, GH, KZ, LC, LK, LR,			
UA, UG, RW: GH, GM, CY, DE,	UZ, VN, YU, ZA KE, LS, MW, MZ DK, ES, FI, FR	E, SG, SI, SK, SL, TJ, TM, A, ZM, ZW, AM, AZ, BY, KG, C, SD, SL, SZ, TZ, UG, ZM, K, GB, GR, IE, IT, LU, MC, I, GA, GN, GQ, GW, ML, MR,	KZ, MD, RU, TJ, TM ZW, AT, BE, CH, NL, PT, SE, TR,			
PRIORITY APPLN. INFO.		US 2001-845727 A				
AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the						

presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence DAHKSEVAHRFKDLGEE and characterized as a serum albumin having a mol. wt. of 1949 daltons was found. This marker is indicative of Syndrome X related diseases.

IT 473546-14-4

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(serum albumin biopolymer marker indicative of Syndrome X diseases having mol. wt. of 1949 daltons)

RN 473546-14-4 CAPLUS

L-Glutamic acid, L-.alpha.-aspartyl-L-alanyl-L-histidyl-L-lysyl-L-seryl-L.alpha.-glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl-Llysyl-L-.alpha.-aspartyl-L-leucylglycyl-L-.alpha.-glutamyl- (9CI) (CA
INDEX NAME)

PAGE 1-B

PAGE 2-A

L11 ANSWER 29 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833392 CAPLUS

DOCUMENT NUMBER:

137:334895

TITLE:

Biopolymer marker indicative of disease state having a molecular weight of

1424 daltons

INVENTOR(S):

Jackowski, George; Stanton, Eric B.; Thatcher, Brad; Vrees, Tammy; Yantha, Jason; Marshall, John

PATENT ASSIGNEE(S):

SOURCE:

Can. U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent English

1

LANGUAGE: FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE						
US 2002160417 A1 20021031 US 2001-845726 20010430 W0 2002088719 A2 20021107 W0 2002-CA593 20020426 W0 2002088719 A3 20021227						
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, C CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, G GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, I LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, G PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, T UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, I RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, I CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, S	GE, GH, LK, LR, OM, PH, TT, TZ, RU, TJ, TM BE, CH,					
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, PRIORITY APPLN. INFO.: US 2001-845726 A 20010430 AB The instant invention involves the use of a combination of preparation of preparations.	ratory					
steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. IT 263562-87-4						

IT RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(biopolymer marker indicative of disease state having a mol. wt. of 1424 daltons)

RN 263562-87-4 CAPLUS

CN L-Lysine, L-alanyl-L-histidyl-L-lysyl-L-seryl-L-.alpha.-glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B